This antibody SI-B001 is an significant development in the treatment of difficult-to-treat multiple myeloma. The unique antibody specifically binds to BCMA on myeloma tumors, triggering immune-mediated cell cytotoxicity and promoting tumor-killing patient's activity. Early investigational data sugge